Fig. 5From: Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center studyBootstrap distribution of cost effectiveness of TOZ versus ADM or ETC for ESR level reductionBack to article page